Tevogen (TVGN) Share-based Compensation (2024 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Share-based Compensation came in at $81.2 million in Q1 2026, up 4345.03% YoY from $1.8 million in Q1 2025, and up 451.91% on a QoQ basis from $14.7 million in Q4 2025.
Tevogen (TVGN) Share-based Compensation (2024 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 3 years of Share-based Compensation data on file, last reported at $81.2 million in Q1 2026.
- Quarterly Share-based Compensation rose 4345.03% year-over-year to $81.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.2 million (up 72.92% YoY) and the FY2025 annual result came in at $83.9 million, up 105.7% from the prior year.
- Share-based Compensation rose to $81.2 million in Q1 2026, from $14.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $81.2 million in Q1 2026 to a low of $1.8 million in Q1 2025.
- A 3-year average of $19.5 million and a median of $4.1 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 93.06% — and 2026, when it surged 4345.03%.
- Tracing TVGN's Share-based Compensation over 3 years: stood at $37.7 million in 2024, then plunged by 60.93% to $14.7 million in 2025, then soared by 451.91% to $81.2 million in 2026.
- The last three Share-based Compensation figures came in at $81.2 million (Q1 2026), $14.7 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.18 Mn |
| Mar 31, 2026 | 81.18 Mn |
| Dec 31, 2025 | 14.71 Mn |
| Dec 31, 2025 | 14.71 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 37.65 Mn |
| Dec 31, 2024 | 37.65 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Mar 31, 2024 | 26.33 Mn |